An understanding of interactions within the tumor microenvironment (TME) of classic
Hodgkin lymphoma (cHL) has helped pave the way to novel immunotherapies that have …

Despite major treatment improvements over the past decades, pediatric acute myeloid
leukemia (AML) is still a life-threatening malignancy with relapse rates up to 30% and …

Tumor microenvironment and immune escape affect pathogenesis and survival in classical
Hodgkin lymphoma (cHL). While tumor-associated macrophage (TAM) content has been …

Aims The programmed death 1 (PD 1)/PD 1 ligand (PD‐L1) axis plays an important role in
tumour cells escape from immune control. PD‐L1 immunohistochemistry is a useful predictor …

Simple Summary Approximately one in seven patients with classical Hodgkin lymphoma
have refractory disease or relapse after standard front line chemotherapy. Prognostic …

In lymphomas of B-cell origin, cancer cells orchestrate an inflammatory microenvironment of
immune and stromal cells that sustain the tumor cell survival and growth, known as a tumor …

ABSTRACT The Hodgkin and Reed–Sternberg (HRS) cells in classical Hodgkin Lymphoma
(cHL) actively modify the immune tumor microenvironment (TME) attracting …

Abstract Interleukin-6 (IL-6) can induce therapeutic resistance for several cancer agents
currently used to treat classical Hodgkin lymphoma (cHL). We aimed to investigate whether …

Emerging evidence indicates a major impact for the tumor microenvironment (TME) and
immune escape in the pathogenesis and clinical course of classical Hodgkin lymphoma …

We studied the expression of programed death 1 (PD-1) receptor and its ligands (PD-L1/-L2)
by immunohistochemistry and its association with clinicopathological features in 81 …